Key Drivers
- Strong cash flow
- Weak liquidity
- Thin profitability
AIAI Summary
ICON's investment case hinges on proving that its AI-enabled clinical-trial platform can translate strong free-cash-flow generation into durable gross-margin recovery and faster growth before elevated debt and accounting-investigation risks deepen its governance discount; investors should wait for measurable AI productivity gains, reporting clarity, and a sustained move above $173–174.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash flow
- •Weak liquidity
- •Thin profitability
ICLR delivers strong cash generation and improving operating leverage, but thin profitability, worsening liquidity, high intangibles, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Failed rebound
- •Key support
- •Weak momentum
ICLR is mildly bearish over the last month, with sellers regaining control below the $167.34 average; watch $158–$160 support and $173–$174 resistance.
Nearly 10% rebound from $158.34 to $173.94 before reversing
Sentiment & News
Key News Insights:
- •Share Price Gain
- •Valuation Upside
- •Winton Stake Cut
ICLR showed modest price strength and potential valuation upside, but Winton Group's 94% stake reduction is the key institutional signal to monitor.
The large institutional sell-down may temper sentiment despite ICLR's recent gains and apparent valuation discount
Similar Companies in Healthcare
Other companies in the same sector with AI ratings